2016
A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors
Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget 2016, 7: 59965-59975. PMID: 27494868, PMCID: PMC5312362, DOI: 10.18632/oncotarget.11015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAntibodies, CatalyticBreast NeoplasmsCell Line, TumorDNADoxorubicinDrug Delivery SystemsFemaleHumansLactic AcidLupus Coagulation InhibitorMammary Neoplasms, AnimalMiceMice, Inbred BALB CNanoparticlesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor MicroenvironmentConceptsDelivery of nanoparticlesDOX-loaded nanoparticlesTumor-targeting mechanismDrug delivery mechanismsAmount of moleculesNanoparticle deliveryLupus anti-DNA autoantibodiesNanoparticlesProof of conceptRelease of DNASurface modificationBind moleculesAutocatalytic effectDelivery mechanismTumor neovasculatureMoleculesDeliveryDoxorubicinTumor microenviromentMajor limitationEfficiencyLigandsSubsequent treatmentToxic agentsDNA
2015
DNA-dependent targeting of cell nuclei by a lupus autoantibody
Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports 2015, 5: 12022. PMID: 26156563, PMCID: PMC4496662, DOI: 10.1038/srep12022.Peer-Reviewed Original ResearchConceptsLupus anti-DNA autoantibodiesAnti-DNA autoantibodiesTumor cell nucleiSingle-chain variable fragmentPotential therapeutic applicationsLupus autoantibodiesTherapeutic approachesIschemic conditionsCertain cancer cellsChain variable fragmentCancer cellsCell nucleiAutoantibodiesNecrotic regionsVariable fragmentTherapeutic applicationsDNA damageNuclear uptakeScFvMalignancyGreater understandingTumorsStrokeDisease
2014
A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells
Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.Peer-Reviewed Original ResearchConceptsLupus autoantibodiesTherapeutic agentsCancer cellsSystemic lupus erythematosusBRCA2-deficient cellsLupus erythematosusBRCA2-deficient cancer cellsDLD1 colon cancer cellsColon cancer cellsSuch antibodiesLower riskAutoantibodiesSpecific cancersAntibodiesMalignancyDifferential effectsToxic effectsPotential utilityCellsAgentsFurther supportDNA-damaging agentsErythematosusTherapyCancer
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise role
2009
Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo.
Heinze E, Baldwin S, Chan G, Hansen J, Song J, Clements D, Aragon R, Nishimura R, Reeves M, Weisbart R. Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. International Journal Of Oncology 2009, 35: 167-73. PMID: 19513564, DOI: 10.3892/ijo_00000325.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalApoptosisBreast NeoplasmsCaspase 3Cell Line, TumorCell SurvivalColorectal NeoplasmsDose-Response Relationship, DrugFemaleForkhead Transcription FactorsHumansImmunoconjugatesImmunoglobulin FragmentsLiver NeoplasmsMiceMice, Inbred BALB COvarian NeoplasmsRecombinant Fusion ProteinsTransfectionConceptsColon cancer metastasisCancer cellsCancer metastasisColon cancer cellsBALB/c miceProtein therapyImmune suppressive functionCell deathDose-dependent cell deathRegulatory cellsTumor burdenClinical efficacySyngeneic modelC miceNuclear transcription factorMouse modelSuppressive functionInhibits metastasisMetastasisZ-VAD-FMKClinical potentialTherapyCaspase-3Foxp3Cell killing
2007
Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo
Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo. Cancer Research 2007, 67: 1769-1774. PMID: 17308119, DOI: 10.1158/0008-5472.can-06-3783.Peer-Reviewed Original ResearchConceptsLiver metastasesMetastasis ScoreBALB/c miceCancer metastasisCancer cellsMediator of intracellularColon cancer metastasisProtein therapySplenic injectionClinical efficacyControl miceDelivery of p53Significant clinical potentialC micePortal veinColon cancer cellsImmunohistochemical stainingMouse modelSecond injectionMetastasisClinical potentialMiceTherapyVivoP53